Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-Dose Prophylactic Gabapentin (HOPE) to Prevent Opioid Use for Oral Mucositis Pain During Head and Neck Chemoradiotherapy: A Phase III Clinical Trial

NCT06992427 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT06992427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06992427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-Dose Prophylactic Gabapentin (HOPE) to Prevent Opioid Use for Oral Mucositis Pain During Head and Neck Chemoradiotherapy: A Phase III Clinical Trial
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
June 5, 2025
Completion date
April 15, 2031
Enrollment
228 (estimated)
Sites
212

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, stage i head and neck cutaneous squamous cell carcinoma ajcc v8, stage ii head and neck cutaneous squamous cell carcinoma ajcc v8, stage iii head and neck cutaneous squamous cell carcinoma ajcc v8, stage iv head and neck cutaneous squamous cell carcinoma ajcc v8